BDS is a front-end player in innovative bio-analytics. Our laboratories include fully equipped Innovation and Development departments with ample experience in developing new bioanalytical tools (including all current CALUX® assays) and their various applications. As such, our proprietary CALUX® methods have been transformed from the classical manual format to high throughput formats using robotics. This also allowed miniaturization to 384-wells format, increasing both throughput and accuracy. Furthermore, in this miniaturised set-up, only a fraction of the original sample volume is required, which is especially relevant when only small sample volumes are available, such as in clinical or epidemiological studies. Comprehensive panels of bioassays have been developed for safety- and activity profiling for various applications. Current research focuses on further expansion of the range of bioanalytical tools and their applications. Those include animal alternatives for activity screens and safety assessments, barcoding methods, and tool development for rapid data interpretation and extrapolation, including assessment of metabolism and pharmacokinetics. In addition, cost reduction, simplification, and on-line technologies are current focal areas of future innovations. Through the metagenomics expertise of partner SME MLS, and fractionation and chemical identification technologies, the bioactivity screening capabilities of BDS will be increasingly used for new bio-based product development. This ambitious program is carried out in close collaboration with other companies and academic groups in the context of many public private partnerships in major national- and international projects.